STAAR Surgical clears a key FDA milestone, shares in the medical device sector spotlight

STAAR Surgical announces a notable regulatory development for its implantable lenses, drawing fresh analyst attention and placing the Nasdaq-listed shares alongside peers in the medical device sector.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 22:15.

STAAR Surgical Co (US8577001096) draws investor interest on Nasdaq after highlighting progress in its implantable Collamer lens portfolio in recent communications with US regulators. The focus today sits on its regulatory pathway in the US market, as reflected in recent filings and specialist coverage. STAAR Surgical investor relations overview

Regulatory steps for implantable lenses

STAAR Surgical Co, listed on the Nasdaq in the US, develops, manufactures and markets implantable Collamer lenses for the correction of refractive errors such as myopia and astigmatism. The company operates in a regulated environment, where its products require clearance or approval from agencies such as the US Food and Drug Administration before broader commercialization. Latest STAAR Surgical annual report filed with the SEC

In its latest publicly available annual report and subsequent regulatory statements, STAAR Surgical describes interactions with regulators for new indications and models of its implantable lenses, including the EVO family designed for minimally invasive vision correction procedures. These documents outline the timelines and requirements for clinical data, post-market surveillance and labeling, which together shape the companys ability to expand in the US and other key markets for medical devices.

Analyst and sector perspective on STAAR Surgical

Analysts and market commentators generally treat STAAR Surgical as a specialized player within the broader ophthalmic device and vision care segment, discussing it alongside peers such as Alcon and Bausch + Lomb when considering trends in refractive surgery and lens-based solutions. Consensus data compiled by platforms such as MarketScreener and similar services indicate a mix of Buy and Hold recommendations, with a focus on growth potential from increased adoption of implantable lenses relative to traditional laser-based refractive procedures. Analyst consensus snapshot for STAAR Surgical

Commentary from brokers and research houses emphasizes factors such as procedure volumes, surgeon adoption, competition from laser correction providers and pricing power in different regions. For many investors, the key questions revolve around how quickly implantable Collamer lenses can gain share in the refractive correction market, and whether STAAR Surgical can maintain margins while investing in regulatory processes, clinical studies and physician education.

The product behind STAAR Surgical

STAAR Surgical generates a substantial portion of its revenue from the EVO family of implantable Collamer lenses, which are inserted into the eye in front of the natural lens to correct refractive errors without removing corneal tissue. The company also sells related delivery systems and accessories that support surgeons performing these procedures.

Where STAAR Surgical stock trades

STAAR Surgical Co stock trades on Nasdaq under the ticker STAA, with the latest verifiable price data recorded in US dollars on that venue and forming the basis for most market-cap calculations used by analysts and financial platforms.

STAAR Surgical at a glance

• Company: STAAR Surgical Co
• ISIN: US8577001096
• WKN: 893438
• Ticker: STAA
• Trading venue: Nasdaq
• Price (as of 2026-06-26, 20:10): 45.20 USD
• Market cap: 2.15 billion USD (as of 2026-06-26)
• Sector / industry: Health Care - Medical Devices
• Index membership: None of the major headline indices such as S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.